PURPOSE: Patients with clinical stage I testicular seminoma have historically been treated with adjuvant radiotherapy in the United States. However, nearly 80% of patients on surveillance will not experience relapse and even with relapse, salvage rates approach 100%. It remains unclear how practice patterns have changed with recently accumulating evidence and changes in guidelines. In a population based setting we evaluated contemporary trends and factors that may affect the use of adjuvant radiotherapy. MATERIALS AND METHODS: A total of 8,151 men diagnosed with stage I testicular seminoma from 2000 to 2009 were identified in the national SEER (Surveillance, Epidemiology, and End Results) registry. A multivariate regression model was constructed to analyze the association of year, age, race, socioeconomic status, SEER region, pathological stage and tumor size with the administration of adjuvant radiotherapy. RESULTS: The use of adjuvant radiotherapy decreased significantly from 2000 to 2009. In 2000, 74.7% of patients received radiation, compared with only 37.7% of patients in 2009 (p <0.0001). Later year of diagnosis was significantly associated with decreased odds of receiving adjuvant radiotherapy (p <0.0001, 2000 to 2005 vs 2006 to 2009, OR 0.40, 95% CI 0.36-0.44). Men age 35 years or older (p <0.0002, OR 1.20, 95% CI 1.09-1.32) and men in the highest socioeconomic index quartile (p <0.0001, OR 1.34, 95% CI 1.16-1.54) were more likely to receive adjuvant radiotherapy. CONCLUSIONS: The use of adjuvant radiotherapy for clinical stage I testicular seminoma has decreased significantly in the last decade. Older age and higher socioeconomic status are associated with higher rates of adjuvant radiotherapy.
PURPOSE:Patients with clinical stage I testicular seminoma have historically been treated with adjuvant radiotherapy in the United States. However, nearly 80% of patients on surveillance will not experience relapse and even with relapse, salvage rates approach 100%. It remains unclear how practice patterns have changed with recently accumulating evidence and changes in guidelines. In a population based setting we evaluated contemporary trends and factors that may affect the use of adjuvant radiotherapy. MATERIALS AND METHODS: A total of 8,151 men diagnosed with stage I testicular seminoma from 2000 to 2009 were identified in the national SEER (Surveillance, Epidemiology, and End Results) registry. A multivariate regression model was constructed to analyze the association of year, age, race, socioeconomic status, SEER region, pathological stage and tumor size with the administration of adjuvant radiotherapy. RESULTS: The use of adjuvant radiotherapy decreased significantly from 2000 to 2009. In 2000, 74.7% of patients received radiation, compared with only 37.7% of patients in 2009 (p <0.0001). Later year of diagnosis was significantly associated with decreased odds of receiving adjuvant radiotherapy (p <0.0001, 2000 to 2005 vs 2006 to 2009, OR 0.40, 95% CI 0.36-0.44). Men age 35 years or older (p <0.0002, OR 1.20, 95% CI 1.09-1.32) and men in the highest socioeconomic index quartile (p <0.0001, OR 1.34, 95% CI 1.16-1.54) were more likely to receive adjuvant radiotherapy. CONCLUSIONS: The use of adjuvant radiotherapy for clinical stage I testicular seminoma has decreased significantly in the last decade. Older age and higher socioeconomic status are associated with higher rates of adjuvant radiotherapy.
Keywords:
CS; CT; EAU; EOD; European Association of Urology; Extent of Disease; NCCN; National Comprehensive Cancer Network; RT; SEER program; SES; adjuvant; chemotherapy; collaborative stage; computerized tomography; radiotherapy; seminoma; socioeconomic status
Authors: L B Travis; R E Curtis; H Storm; P Hall; E Holowaty; F E Van Leeuwen; B A Kohler; E Pukkala; C F Lynch; M Andersson; K Bergfeldt; E A Clarke; T Wiklund; G Stoter; M Gospodarowicz; J Sturgeon; J F Fraumeni; J D Boice Journal: J Natl Cancer Inst Date: 1997-10-01 Impact factor: 13.506
Authors: M G Mulla; G Ananthkrishnan; M S Mirza; P Bungay; S Puri; P Chakraborti Journal: Clin Oncol (R Coll Radiol) Date: 2007-02-08 Impact factor: 4.126
Authors: Jorge Aparicio; Pablo Maroto; Xavier García del Muro; Josep Gumà; Alfonso Sánchez-Muñoz; Mireia Margelí; Montserrat Doménech; Romá Bastús; Antonio Fernández; Marta López-Brea; Josefa Terrassa; Andrés Meana; Purificación Martínez del Prado; Javier Sastre; Juan J Satrústegui; Regina Gironés; Lidia Robert; José R Germà Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544
Authors: Robert Abouassaly; Sophie D Fossa; Aleksander Giwercman; Christian Kollmannsberger; Robert J Motzer; Hans-Joachim Schmoll; Cora N Sternberg Journal: Eur Urol Date: 2011-06-12 Impact factor: 20.096
Authors: Reshma Jagsi; Paul Abrahamse; Sarah T Hawley; John J Graff; Ann S Hamilton; Steven J Katz Journal: Cancer Date: 2011-06-29 Impact factor: 6.860
Authors: R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning Journal: Lancet Date: 2005 Jul 23-29 Impact factor: 79.321